IP Library Granted Patent US 7,476,390
Granted Patent B2
US 7,476,390 · App. 10/375,932 · Granted Jan 13, 2009

Patent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,476,390
App. No.
10/375,932
Granted
Jan 13, 2009
Kind
B2
Abstract

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.

Claims (14)

1. A non-naturally occurring polypeptide comprising a polypeptide sequence having at least 95% sequence identity to the polypeptide sequence of SEQ ID NO:251, wherein said polypeptide induces production of neutralizing antibodies against at least one dengue virus.

2. The polypeptide of claim 1 , wherein said at least one dengue virus is selected from the group consisting of dengue-1, dengue-2, dengue-3, and dengue-4.

3. The polypeptide of claim 1 , wherein said polypeptide comprises a polypeptide sequence having at least 96% sequence identity to the polypeptide sequence of SEQ ID NO:251, wherein said polypeptide induces production of neutralizing antibodies against at least two dengue viruses of different serotypes selected from the group consisting of dengue-1, dengue-2, dengue-3, and dengue-4.

4. A composition comprising the polypeptide of claim 1 and a carrier.

5. The composition of claim 4 , wherein the carrier is a pharmaceutically acceptable carrier.

6. The polypeptide of claim 1 , wherein said polypeptide comprises a polypeptide sequence having at least 97% sequence identity to the polypeptide sequence of SEQ ID NO:251.

7. The polypeptide of claim 6 , wherein said polypeptide comprises a polypeptide sequence having at least 98% sequence identity to the polypeptide sequence of SEQ ID NO:251.

8. The polypeptide of claim 7 , wherein said polypeptide comprises the polypeptide sequence of SEQ ID NO:251.

9. The polypeptide of claim 7 , wherein said polypeptide comprises a polypeptide sequence having at least 99% sequence identity to the polypeptide sequence of SEQ ID NO:251.

10. The polypeptide of claim 6 , wherein said at least one dengue virus is selected from the group consisting of dengue-1, dengue-2, dengue-3, and dengue-4.

11. A non-naturally occurring polypeptide comprising a polypeptide sequence having at least 95% sequence identity to the polypeptide sequence of SEQ ID NO:251, wherein said polypeptide induces an immune response against at least one dengue virus.

12. The polypeptide of claim 11 , wherein said at least one dengue virus is selected from the group consisting of dengue-1, dengue-2, dengue-3, and dengue-4.

13. The polypeptide of claim 12 , wherein said polypeptide induces an immune response against at least two dengue viruses of different serotypes selected from the group consisting of dengue-1, dengue-2, dengue-3, and dengue-4.

14. A composition comprising the polypeptide of claim 11 and a carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2011
From: MAXYGEN, INC.
To: ALTRAVAX, INC.
Reel/Frame 027081/0534 →
CONFIRMATORY LICENSE Recorded Dec 8, 2003
From: MAXYGEN, INC.
To: NAVY SECRETARY OF THE UNITED STATES
Reel/Frame 014790/0747 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2003
From: DORIS APT.; PUNNONEN, JUHA; BRINKMAN, ALICE M.
To: MAXYGEN, INC.
Reel/Frame 014465/0075 →